B7-H3 CAR T
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for B7-H3 CAR T, covering 2022-12-28 to 2025-11-20. Get the full timeline:
Most recent: Clinical Trial Update: Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors [Phase 1]